

Sorin Group Factsheet

- Sorin Group is a global medical device company and a leader in the treatment of cardiovascular diseases
- Sorin Group develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders
- Sorin Group's products improve the health and the quality of life of more than 1 million patients in 100 countries every year
- Sorin Group focuses on two major therapeutic areas:
 - Cardiac surgery (67% of revenues): As a world leader in cardiac surgery, Sorin Group provides a wide range of innovative therapeutic solutions for both open heart and minimally-invasive cardiac surgery, cardiopulmonary products for open heart surgery and heart valve repair or replacement products.



- Cardiac Rhythm Management (33% of revenues): As a major global player in cardiac rhythm management, Sorin Group's portfolio offers innovative options that address the needs of patients and healthcare professionals: from implantable cardiac defibrillators and pacemakers to systems for cardiac resynchronization therapy (CRT), patient management, and arrhythmia assessment.



- Broken down by geography in 2014, sales in Europe constitute 52%, USA 23%, Japan 7%, and 18% from the rest of the world

Facts and Figures

- 2014 Revenues: €746.9m
- Adjusted Net profit of €55.1m
 - €10.0m negative FX impact
 - €5.3m impact from new ventures
- Net financial debt at €124.4m, corresponding to 1.0x Net Debt/EBITDA
- Current headquarters: Milan, Italy
- Stock Exchange: Italian Stock Exchange
- Market capitalisation: €1,010.1m (as of 16th February 2015)
- Employees: approximately 3,900
- Global reach: Manufacturing and R&D facilities in Brazil, Belgium, Canada, China (under development), Dominican Republic, France, Germany, Italy and the United States
- Focus on R&D: €80m of R&D expenses (11% of revenues) in 2014

Sorin Group Factsheet





CEO: ANDRÉ-MICHEL BALLESTER

André-Michel Ballester was appointed CEO in September 2007. Since 2004, he has been President of Sorin's Cardiac Rhythm Management Business Unit.


André-Michel was, from 2000 to 2004, Corporate Vice President EMEA, Asia and Latin America for Edwards Lifesciences.

André-Michel spent his professional background in Edwards Lifesciences and Baxter, where he participated in the successful spinoff of Edwards Lifesciences from Baxter. For over 10 years prior to Edwards' spin-off, André-Michel held several executive positions in Baxter in Europe and in the USA.

Current R&D and production locations



Sales by Geographical Area



Shareholder Structure

